Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 970Neoplasms 767Carcinoma, Non-Small-Cell Lung 750Prostatic Neoplasms 577Colorectal Neoplasms 503Lung Neoplasms 447Neoplasm Metastasis 408Multiple Myeloma 376Leukemia, Myeloid, Acute 358Ovarian Neoplasms 311Pancreatic Neoplasms 306Melanoma 275Squamous Cell Carcinoma of Head and Neck 259Recurrence 248Carcinoma, Hepatocellular 233Glioblastoma 225Brain Neoplasms 221Head and Neck Neoplasms 202Triple Negative Breast Neoplasms 200Carcinoma, Renal Cell 200Lymphoma 192Precursor Cell Lymphoblastic Leukemia-Lymphoma 191Stomach Neoplasms 189Endometrial Neoplasms 179Lymphoma, Non-Hodgkin 175Sarcoma 169Glioma 168Uterine Cervical Neoplasms 167Lymphoma, Large B-Cell, Diffuse 160Hematologic Neoplasms 159

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Castrate Sensitive Prostate Cancer × 90 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡